Searched for
RETINAL DEGENERATION
US Stocks: Kodiak Sciences shares soar 68% after eye drug succeeds in late-stage studyShares of Kodiak Sciences surged 68.6% to their highest in more than four years on Thursday after the drug developer's experimental drug me...- Zydus Lifesciences in focus after USFDA clears Ahmedabad plant, Aflibercept biosimilar launchZydus Lifesciences is in focus after receiving USFDA clearance with zero observations for its Ahmedabad facility and launching ANYRA, India...
- Eyestem receives CDSCO approval to initiate Phase 2 randomised, controlled human trials of Eyecyte-RPEEyestem Research has secured approval from India's CDSCO to begin Phase 2 clinical trials for its Eyecyte-RPE cell therapy. This treatment ...
- Lupin inks licensing deal to supply biosimilar ranibizumab in Latin AmericaLupin, an Indian drug maker, partners with SteinCares. The agreement focuses on ranibizumab's commercialisation. Latin America, excluding M...
- Eyestem’s Eyecyte-RPE trial shows vision rescue for geographic atrophy patientsEyestem will be presenting its data at the ARVO 2025 Annual Meeting as well as the 10th Retinal Cell and Gene Therapy Innovation Summit in ...
- USFDA approves Biocon Biologics' biosimilar product to treat ophthalmology conditionsBiocon Biologics received US Food and Drug Administration (USFDA) approval for biosimilar Yesafili, a vascular endothelial growth factor in...
- Lupin ties up with Amman Pharma for commercialisation of biosimilar productLupin has inked a licensing pact for the commercialisation and marketing of Ranibizumab, a biosimilar of Lucentis, in various countries inc...
- Eyestem partners with RetinAI for treatment of geographic atrophy with AI techGeographic atrophy can lead to irreversible loss of vision over time and currently affects 200 million people globally.
- Shilpa Medicare arm gets NoC to conduct clinical studies for its Biosimilar AfliberceptListed pharmaceutical entity Shilpa Medicare on Monday informed the exchanges that its subsidiary Shilpa Biologicals (SBPL) has received a ...
- Do you experience flashes of light, distortion of images, cloudy vision? Screening for retinal diseases early can be beneficialIt is important for everyone to detect drop in vision at the earliest stage.
- Blue light from digital devices could accelerate blindnessWashington, Aug 13 (IANS) Blue light from digital devices including smartphones could accelerate blindness, researchers have found.
- Glaucoma, that can lead to blindness, may be an autoimmune diseaseAutoimmune disease is a condition in which the immune system attacks the body's own cells.
- Fish eyes may help cure blindness in humans, says studyIt turns out that the structure of the retinas of fish and mammals are basically the same.
- New technique for early detection of human eye diseasesKolkata, Dec 27 (IANS) A software analysis can now highlight the subtle differences between a diseased and healthy retina, a development th...
- New gene editing technique may treat inherited blindnessRetinitis pigmentosa is a class of diseases in which patients experience night blindness in the early stages, along with atrophy and pigmen...
- Surgeons, a step closer to curing blindnessSurgeons in the UK have carried out a pioneering human embryonic stem cell operation in their efforts to find a cure for age-related blindn...
- Study says loss of retina cells could be early sign of FTD in patients with genetic riskA new study has discovered that the loss of retina cells could be one of the earliest signs of FTD in patients with a genetic risk for the ...
- New hand-held device to catch early signs of eye diseaseMIT researchers have developed a new hand-held device that scans a patient's entire retina in seconds to detect a host of retinal diseases.
- Sun Pharma gains on JV to develop new drugsThe joint venture will leverage Sun Pharma’s global capabilities and experience in developing and manufacturing complex dosage forms and sp...
- Sun Pharma inks JV with US-based Intrexon Corp to develop gene therapiesThe 50:50 deal will leverage Sun Pharma’s global capabilities and experience in developing complex dosage forms and specialty pharmaceutica...
Load More
